 |
|
Transthyretin-Related Familial Amyloidotic Polyneuropathy
Yukio Ando, MD;
Masaaki Nakamura, MD;
Shukuro Araki, MD
Arch Neurol. 2005;62:1057-1062.
Transthyretin-related familial amyloidotic polyneuropathy (FAP) is a fatal hereditary amyloidosis. Until 20 years ago, FAP was thought to be restricted to endemic occurrence in certain areas. However, owing to progress in biochemical and molecular genetic analyses, FAP is now believed to occur worldwide. As of today, reports of about 100 different points of single or double mutations, or a deletion in the transthyretin gene, have been published, and several different phenotypes of FAP have been documented, even for the same mutation in the transthyretin gene. We present herein the current clinicopathological, biochemical, molecular genetic, and epidemiological aspects of transthyretin-related FAP, and we introduce a new diagnostic procedure for the disease.
Author Affiliations: Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan (Drs Ando and Nakamura); and Department of Neurology, Ohmuta Tenryo Hospital, Ohmuta Fukuoka, Japan (Dr Araki).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
SELDI-TOF Mass Spectrometry Evaluation of Variant Transthyretins for Diagnosis and Pathogenesis of Familial Amyloidotic Polyneuropathy
Ueda et al.
Clin. Chem. 2009;55:1223-1227.
ABSTRACT
| FULL TEXT
A father and his son with systemic AL amyloidosis
Enqvist et al.
haematol 2009;94:437-439.
FULL TEXT
A Case of Polyneuropathy and Proteinuria
Korbet and Bonsib
CJASN 2008;3:624-636.
FULL TEXT
|
